Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 2/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 14/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | CDK4 | P11802 | 1/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | CCND1 | P24385 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13553621 | 0.92 | TNK2 (0.40) | PAK1TNK2SRC | |
| SCHEMBL15785306 | 0.81 | TNK2 (0.42) | TNK2SRC | |
| SCHEMBL16309174 | 0.80 | PAK1 (0.43) | PAK1TNK2SRCFGFR1CDK4 | |
| SCHEMBL15787929 | 0.77 | STK4 (0.38) | PAK1TNK2SRCFGFR1CDK4 | |
| SCHEMBL15041482 | 0.77 | TNK2 (0.42) | TNK2SRC | |
| SCHEMBL15041260 | 0.77 | RIPK2 (0.39) | TNK2SRCFGFR1CDK4CCNA2 | |
| SCHEMBL14681970 | 0.76 | PRKDC (0.43) | PAK1TNK2SRC | |
| SCHEMBL15041473 | 0.76 | PAK1 (0.46) | PAK1TNK2SRCFGFR1PAK2 | |
| SCHEMBL13553886 | 0.76 | PAK1 (0.44) | PAK1TNK2SRCFGFR1 | |
| SCHEMBL13553844 | 0.76 | PAK1 (0.43) | PAK1TNK2FGFR1CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK1 4/4885TNK2 7/4885SRC 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.